Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous vedolizumab in pediatric ulcerative colitis or Crohn's disease
MOH_2017-09-18_000675Phase 2Completed
- Sponsor
- Takeda
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vedolizumab in autoimmune colitis and Crohn's disease (2 arms), sponsored by Takeda. Primary endpoints: Pharmacokinetics of vedolizumab, Safety of vedolizumab and 1 more. Started Sep 2017; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on MOH_2017-09-18_000675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-18_000675.